Description

Simple

A medication used to prevent and treat bleeding in blood clotting disorders or from treatment with certain blood thinners.

Clinical

A Factor IX complex used to prevent and treat bleeding episodes in hemophilia B or vitamin K antagonist therapy.

Overview

Factor IX Complex is a sterile, lyophilized concentrate composed of a number of Vitamin K-dependent clotting factors found in functioning human plasma. Also known as prothrombin complex concentrate, products containing this complex often include Factor IX (antihemophilic factor B), Factor II (prothrombin), Factor X (Stuart-Prower Factor), and low levels of Factor VII (proconvertin) derived from human plasma. Many commercially available products also contain low levels of other antithrombotic proteins. For example, Kcentra (FDA) also contains the antithrombotic proteins C and S, while Bebulin VH (FDA) contains heparin. Coagulation factors are purified from pooled human plasma and subsequently sterilized and treated.

Although Factor IX Complex products contain many different coagulation components, Factor IX is the lead component for potency and efficacy, particularly when used for the treatment of bleeding associated with Hemophilia B (Factor IX deficiency). As the product Kcentra, Factor IX Complex is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients experiencing acute major bleeding or requiring rapid reversal of therapy.

Pharmacology

Indication

Factor IX Complex is indicated for the prevention and control of hemorrhagic episodes in hemophilia B patients. It is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major blee... Read more

Pharmacodynamic

Information currently not available.

Mechanism of action

Factor IX Complex is a sterile, lyophilized concentrate composed of a number of Vitamin K-dependent clotting factors found in functioning human plasma. Also known as prothrombin complex concentrate, products containing this complex often include Factor IX (antihemophilic factor B), Factor II (prothr... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Factor IX Complex (Human)
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with (R)-warfarin.
(S)-Warfarin
The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with (S)-Warfarin.
4-hydroxycoumarin
The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with 4-hydroxycoumarin.
Abciximab
The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Abciximab.
Acenocoumarol
The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Acenocoumarol.
Acetylsalicylic acid
The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Acetylsalicylic acid.
Alpha-1-proteinase inhibitor
Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Factor IX Complex (Human).
Alteplase
The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Alteplase.
Amediplase
The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Amediplase.
Aminocaproic acid
The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Factor IX Complex (Human).
Aminomethylbenzoic acid
Aminomethylbenzoic acid may increase the thrombogenic activities of Factor IX Complex (Human).
Anagrelide
The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Anagrelide.
Ancrod
The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Ancrod.
Anistreplase
The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Anistreplase.
Antithrombin Alfa
The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Antithrombin Alfa.
Antithrombin III human
The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Antithrombin III human.
Apixaban
The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Apixaban.
Aprotinin
Aprotinin may increase the thrombogenic activities of Factor IX Complex (Human).
Ardeparin
The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Ardeparin.
Argatroban
The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Argatroban.
3 References
  1. 1 . Hedges A, Coons JC, Saul M, Smith RE: Clinical effectiveness and safety outcomes associated with prothrombin complex concentrates. J Thromb Thrombolysis. 2016 Jul;42(1):6-10. doi: 10.1007/s11239-015-1321-4.PubMed: 26685667
  2. 2 . Sin JH, Berger K, Lesch CA: Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation. J Crit Care. 2016 Jul 5;36:166-172. doi: 10.1016/j.jcrc.2016.06.024.PubMed: 27546767
  3. 3 . Chai-Adisaksopha C, Hillis C, Siegal DM, Movilla R, Heddle N, Iorio A, Crowther M: Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost. 2016 Aug 4;116(4).PubMed: 27488143